Spinal Muscular Atrophy Therapeutics: Where do we Stand?

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder characterized by motor neuron degeneration and muscle atrophy.
• Motor neuron loss leads to severe muscle weakness, often fatal in infants, while milder forms present progressive weakness over years.
• SMA is caused by SMN1 gene loss, with reduced functional survival motor neuron (SMN) protein due to alternative splicing of the SMN2 gene.

Purpose of the Study:

• To review current therapeutic strategies for spinal muscular atrophy (SMA).
• To highlight advancements in drug development and gene therapy for SMA.
• To discuss the potential for effective SMA treatments based on recent translational research.

Main Methods:

• Review of therapeutic strategies targeting SMN2 gene expression.
• Analysis of approaches modulating SMN2 pre-mRNA splicing.
• Evaluation of gene therapy as a method to replace SMN1.

Main Results:

• Development of SMA mouse models has facilitated identification of therapeutic targets.
• Promising drug pipeline for SMA has emerged over the last two decades.
• Therapeutic strategies include activating SMN2 expression, modulating its splicing, and gene replacement.

Conclusions:

• Despite no current effective treatments, significant progress has been made in SMA research.
• Translational research over two decades has led to a promising drug pipeline.
• Effective treatments for SMA are now within reach through various therapeutic strategies.